Harriet Kluger MD

Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program

Departments & Organizations

Yale Medical GroupCancer Center, Yale: Prostate and Urologic Cancers Program; Melanoma Program; Developmental TherapeuticsSkin Diseases Research Center, Yale | SPORE in Skin CancerMedical OncologyDiscovery to Cure InternshipImmunology and ImmunotherapyGeneral Urology | Medical Oncology

Research Interests

Prognostic and predictive markers in melanoma and renal cell carcinoma; Development of new drugs for melanoma and renal cell carcinoma more...


  • M.D., Tel Aviv University, 1993

Selected Publications

  • C-Raf is Associated with Disease Progression and Inhibition of Apoptosis in a Subset of Melanomas Jilaveanu LB, Zito C, Aziz SA, Schmitz JC, Sznol M, Camp RL, Rimm DL, and Kluger HM 2009 Sep 15;15(18):5704-13, Clinical Cancer Research
  • Phospho-inositol-3 kinase (PI3K) as a therapeutic target in melanoma Aziz SA, Davies M, Pick E, Zito C, Camp RL, Rimm DL, Kluger Y and Kluger HM 2009 May 1;15(9):3029-36, Clinical Cancer Research
  • Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, and Kluger HM Clinical Cancer Research, 2009 Feb 1;15(3):1076-85



Latest News


Edit Profile